I would imagine that the strategy has to be to get Apabetalone filed for Breakthrough Therapy designation and then wait for the FDA to make up their minds.  

I can't imagine that RVX would go all the way to file for BT designation without the explicit encouragement of the FDA.  Recall that we never heard of BT before Nov 13 (when RVX presented to the FDA), and nothing but BT after Nov 15.

Getting BT would ratchet up the price that RVX would command from a buyer, based on similar approvals for other companies, historically speaking.  I understand that getting BT knocks off 2 years from any future trials.  

FWIW, I think C$6 is your bargain basement price for RVX.  Don't forget that there are C$400 million tax loss carry forwards which need to be accounted for, in any buyout.

Fingers crossed...let's hope RVX lives to fight another day by raising sufficient capital.  

Iconoclast